ClinicalTrials.gg
TerminatedNCT03248492Updated Jun 26, 2025Results posted

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

A Phase 2 interventional study of DS-8201a in Breast Cancer, sponsored by Daiichi Sankyo. Terminated at 99 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-26.

Sponsored by Daiichi Sankyo · Phase 2, Interventional, and Treatment

Why this study was terminated
The last participant was transitioned to alternative study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
253
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms — 31 open to participants now, 45 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.

Enrollment
13th of 58
253 · median 139
Started
2017
with 1 other
Phase 2
33 of 58
23 open now
Registered
1st of 58
by date
Lead sponsor
9 of 58
Daiichi Sankyo

Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 13th largest by enrollment, is one of 2 that started in 2017, is one of 33 in phase 2, and was the 1st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

31 of the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

Some human epidermal growth factor receptor 2 (HER-2) breast cancer patients do not respond or become resistant to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may slow down tumor growth. This might improve outcomes for these patients.

03

Conditions studied

  • Breast Cancer

Keywords

  • HER-2 positive breast cancer
  • Metastatic or Unresectable
  • Resistant or refractory to T-DM1
  • DESTINY - Breast 01
  • Trastuzumab deruxtecan
  • T-DXd
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women the age of majority in their country
  • Has documented breast cancer that:

    1. is unresectable or
    2. has positive expression confirmed per protocol
  • Has an adequate tumor sample
  • Has at least one per (RECIST) version 1.1
  • Has protocol-defined adequate cardiac, renal and hepatic function
  • Agrees to follow protocol-defined method(s) of

Exclusion criteria

Exclusion Criteria:

  • Has a medical history of myocardial infarction, symptomatic congestive heart failure (CHF) ( classes II-IV), unstable angina or serious cardiac arrhythmia
  • Has a interval (QTc) prolongation to > 450 millisecond (ms) in males and > 470 ms in females
  • Has a medical history of lung disease
  • Is suspected to have certain other protocol-defined diseases based on imaging at screening period
  • Has history of any disease, condition, drug/medication use or other condition that might, per protocol or in the opinion of the investigator, compromise:

    1. safety or well-being of the participant or offspring
    2. safety of study staff
    3. analysis of results
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
253 participants (actual)

Study arms

  • Experimental
    DS-8201a Low Dose

    T-DM1 resistant/refractory (R/R) patients in the low dose treatment group

    Drug: DS-8201a

  • Experimental
    DS-8201a Medium Dose

    T-DM1 resistant/refractory (R/R) patients in the medium dose treatment group

    Drug: DS-8201a

  • Experimental
    DS-8201a High Dose

    T-DM1 resistant/refractory (R/R) patients in the high dose treatment group

    Drug: DS-8201a

  • Other
    Exploratory Arm

    In Part 2b- Continuation Stage, about 10 T-DM1 Intolerant patients will receive the DS-8201a recommended dose (RD) as an exploratory arm

    Drug: DS-8201a

Interventions

  • DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as low, medium and high intravenous (IV) doses for Part 1 of the trial. The dose for Part 2 will be determined based on results from Part 1.

    Also known as: Experimental product

06

What researchers measure

Primary outcomes

  1. Objective Response Rate as Confirmed by Independent Central Review Following Intravenous Administration of 5.4 mg/kg DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)

    The number of participants with objective response was assessed every six weeks from Cycle 1 Day 1 through discontinuation of treatment, by independent central imaging facility review based on RECIST version 1.1.

    Time frame: at least 6 months after last participant enrolled received first dose up to 19 months (data cut off)

Secondary outcomes

  1. Objective Response Rate as Confirmed By the Investigator Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)

    The number of participants with objective response is assessed every six weeks from Cycle 1 Day 1 through discontinuation of treatment. Investigator-assessed objective response rate (ORR) was defined as the proportion of participants who achieved a best overall response of complete response or partial response based on local radiologists/investigators' tumor assessments.

    Time frame: at least 6 months after last participant enrolled received first dose up to 19 months (data cut off)

  2. Best Overall Tumor Response as Confirmed By the Investigator Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)

    Best overall tumor response was defined as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) by the investigator based on RECIST v1.1. Participants who were non-evaluable (NE) are also reported.

    Time frame: at least 6 months after last participant enrolled received first dose up to 19 months (data cut off)

  3. Disease Control Rate and Clinical Benefit Rate as Confirmed by Independent Central Review Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)

    Number of participants with controlled disease and who received clinical benefit from treatment as assessed by independent central review. DCR was defined as the proportion of participants who achieved a best overall response of complete response, partial response, or stable disease. CBR was defined as the proportion of participants who achieved a best overall response of complete response or partial response or more than 6 months of stable disease.

    Time frame: at least 6 months after last participant enrolled received first dose up to 19 months (data cut off)

  4. Duration of Response (Complete Response or Partial Response) as Confirmed by Independent Central Review Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)

    The estimated duration of confirmed response (complete response \[CR\] or partial response \[PR\]) was assessed by independent central review. Duration of response was defined as the time interval between the date of first documentation of objective response (CR or PR) and the date of the first objective documentation of disease progression or death due to any cause.

    Time frame: at least 6 months after last participant enrolled received first dose up to 19 months (data cut off)

  5. Progression-Free Survival Estimate As Confirmed by Independent Central Review Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)

    The point estimate of progression-free survival (PFS) is reported. PFS was defined as the time interval between the date of randomization/registration and the first documentation of disease progression or death due to any cause.

    Time frame: at least 6 months after last participant enrolled received first dose up to 19 months (data cut off)

  6. Percent Change From Baseline in Sum of Diameters Over Time as Determined by Independent Central Review Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)

    Best percent change in sum of diameters of measurable tumors was based on RECIST 1.1. The best percent change was defined as the percent change in the smallest sum of diameters from all post-baseline tumor assessments, taking as reference the baseline sum of diameters.

    Time frame: Baseline up to Week 6, 12, 18, 24, 30, 36 post dose

  7. Overall Summary of Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Safety Analysis Set)

    TEAEs were assessed by severity and seriousness according to unique criteria. Severity described the intensity of an event and was graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03, where Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL); Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4: Life-threatening consequences; urgent intervention indicated; and Grade 5: Death related to AE. Serious TEAEs were defined as any untoward medical occurrence that at any dose results in death, is life threatening, requires inpatient hospitalization, or causes prolongation of existing hospitalization.

    Time frame: Day 0 to Day 47 post last dose

07

Results

Posted Feb 17, 2020

Participant flow

Participants who met all of the inclusion and none of the exclusion criteria were enrolled and randomized to treatment (Part 1) or received DS-8201a at the recommended dose (Part 2).

Participant flow — Overall Study
MilestonePart 1: DS-8201a Low DosePart 1: DS-8201a Medium DosePart 1: DS-8201a High DosePart 2a: DS-8201a Low DosePart 2b (Exploratory): DS-8201a Low Dose
Started5048211304
Completed00000
Not completed5048211304
Withdrew: Progressive disease242311661
Withdrew: Adverse event14139222
Withdrew: Withdrawal by subject54081
Withdrew: Physician decision11170
Withdrew: Death11060
Withdrew: Study terminated by sponsor31070
Withdrew: Other250140

Outcome measures

PrimaryObjective Response Rate as Confirmed by Independent Central Review Following Intravenous Administration of 5.4 mg/kg DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)

The number of participants with objective response was assessed every six weeks from Cycle 1 Day 1 through discontinuation of treatment, by independent central imaging facility review based on RECIST version 1.1.

Time frame:
at least 6 months after last participant enrolled received first dose up to 19 months (data cut off)
Reported as:
Count of participants · Participants
Objective Response Rate as Confirmed by Independent Central Review Following Intravenous Administration of 5.4 mg/kg DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)
ParticipantsPart 1 and Part 2a: DS-8201a Low DosePart 1 + Part 2a + Part 2b: DS-8201a Low Dose
Objective Response Rate as Confirmed by Independent Central Review Following Intravenous Administration of 5.4 mg/kg DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)109111
SecondaryObjective Response Rate as Confirmed By the Investigator Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)

The number of participants with objective response is assessed every six weeks from Cycle 1 Day 1 through discontinuation of treatment. Investigator-assessed objective response rate (ORR) was defined as the proportion of participants who achieved a best overall response of complete response or partial response based on local radiologists/investigators' tumor assessments.

Time frame:
at least 6 months after last participant enrolled received first dose up to 19 months (data cut off)
Reported as:
Count of participants · Participants
Objective Response Rate as Confirmed By the Investigator Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)
ParticipantsPart 1 and Part 2a: DS-8201a Low DosePart 1 + Part 2a + Part 2b: DS-8201a Low DosePart 1: DS-8201a Medium DosePart 1: DS-8201a High Dose
Objective Response Rate as Confirmed By the Investigator Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)1161183718
SecondaryBest Overall Tumor Response as Confirmed By the Investigator Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)

Best overall tumor response was defined as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) by the investigator based on RECIST v1.1. Participants who were non-evaluable (NE) are also reported.

Time frame:
at least 6 months after last participant enrolled received first dose up to 19 months (data cut off)
Reported as:
Count of participants · Participants
Best Overall Tumor Response as Confirmed By the Investigator Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)
ParticipantsPart 1: DS-8201a Medium DosePart 1: DS-8201a High DosePart 1 + Part 2a: DS-8201a Low DosePart 1 + Part 2a + Part 2b: DS-8201a Low Dose
Complete response3046
Partial response3418112112
Stable disease1035961
Progressive disease0044
Non-evaluable1011
SecondaryDisease Control Rate and Clinical Benefit Rate as Confirmed by Independent Central Review Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)

Number of participants with controlled disease and who received clinical benefit from treatment as assessed by independent central review. DCR was defined as the proportion of participants who achieved a best overall response of complete response, partial response, or stable disease. CBR was defined as the proportion of participants who achieved a best overall response of complete response or partial response or more than 6 months of stable disease.

Time frame:
at least 6 months after last participant enrolled received first dose up to 19 months (data cut off)
Reported as:
Count of participants · Participants
Disease Control Rate and Clinical Benefit Rate as Confirmed by Independent Central Review Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)
ParticipantsPart 1: DS-8201a Medium DosePart 1: DS-8201a High DosePart 1 + Part 2a: DS-8201a Low DosePart 1 + Part 2a + Part 2b: DS-8201a Low Dose
Disease control rate4721175179
Clinical benefit rate4120127130
SecondaryDuration of Response (Complete Response or Partial Response) as Confirmed by Independent Central Review Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)

The estimated duration of confirmed response (complete response \[CR\] or partial response \[PR\]) was assessed by independent central review. Duration of response was defined as the time interval between the date of first documentation of objective response (CR or PR) and the date of the first objective documentation of disease progression or death due to any cause.

Time frame:
at least 6 months after last participant enrolled received first dose up to 19 months (data cut off)
Reported as:
Median · months
Duration of Response (Complete Response or Partial Response) as Confirmed by Independent Central Review Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)
monthsPart 1: DS-8201a Medium DosePart 1: DS-8201a High DosePart 1 + Part 2a: DS-8201a Low DosePart 1 + Part 2a + Part 2b: DS-8201a Low Dose
Duration of Response (Complete Response or Partial Response) as Confirmed by Independent Central Review Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)NA (8.3 to NA)6.0 (4.8 to 8.3)NA (NA to NA)NA (NA to NA)
SecondaryProgression-Free Survival Estimate As Confirmed by Independent Central Review Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)

The point estimate of progression-free survival (PFS) is reported. PFS was defined as the time interval between the date of randomization/registration and the first documentation of disease progression or death due to any cause.

Time frame:
at least 6 months after last participant enrolled received first dose up to 19 months (data cut off)
Reported as:
Median · months
Progression-Free Survival Estimate As Confirmed by Independent Central Review Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)
monthsPart 1: DS-8201a Medium DosePart 1: DS-8201a High DosePart 1 + Part 2a: DS-8201a Low DosePart 1 + Part 2a + Part 2b: DS-8201a Low Dose
Progression-Free Survival Estimate As Confirmed by Independent Central Review Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)NA (NA to NA)9.5 (7.4 to 13.2)NA (10.6 to NA)NA (10.6 to NA)
SecondaryPercent Change From Baseline in Sum of Diameters Over Time as Determined by Independent Central Review Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)

Best percent change in sum of diameters of measurable tumors was based on RECIST 1.1. The best percent change was defined as the percent change in the smallest sum of diameters from all post-baseline tumor assessments, taking as reference the baseline sum of diameters.

Time frame:
Baseline up to Week 6, 12, 18, 24, 30, 36 post dose
Reported as:
Mean · Percent change from baseline
Percent Change From Baseline in Sum of Diameters Over Time as Determined by Independent Central Review Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)
Percent change from baselinePart 1: DS-8201a Medium DosePart 1: DS-8201a High DosePart 1 + Part 2a: DS-8201a Low DosePart 1 + Part 2a + Part 2b: DS-8201a Low Dose
Baseline to Week 6-26.2 ± 18.3-32.9 ± 25.4-26.9 ± 21.6-26.9 ± 22.5
Baseline to Week 12-39.6 ± 22.7-43.6 ± 28.1-39.9 ± 24.5-40.1 ± 24.9
Baseline to Week 18-50.1 ± 22.1-58.5 ± 29.4-44.4 ± 27.8-44.9 ± 28.0
Baseline to Week 24-56.3 ± 22.1-61.9 ± 32.0-49.2 ± 30.6-49.3 ± 30.5
Baseline to Week 30-59.1 ± 26.1-63.9 ± 32.2-51.2 ± 29.2-51.5 ± 29.2
Baseline to Week 36-61.0 ± 26.7-54.6 ± 32.2-55.5 ± 29.9-55.5 ± 29.9
Best percent change from baseline-59.5 ± 28.2-65.3 ± 27.7-50.5 ± 28.3-50.6 ± 28.8
SecondaryOverall Summary of Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Safety Analysis Set)

TEAEs were assessed by severity and seriousness according to unique criteria. Severity described the intensity of an event and was graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03, where Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL); Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4: Life-threatening consequences; urgent intervention indicated; and Grade 5: Death related to AE. Serious TEAEs were defined as any untoward medical occurrence that at any dose results in death, is life threatening, requires inpatient hospitalization, or causes prolongation of existing hospitalization.

Time frame:
Day 0 to Day 47 post last dose
Reported as:
Count of participants · Participants
Overall Summary of Treatment-emergent Adverse Events (TEAEs) Following Intravenous Administration of DS-8201a in Participants With Metastatic Breast Cancer (Safety Analysis Set)
ParticipantsPart 1: DS-8201a Low DosePart 1: DS-8201a Medium DosePart 1: DS-8201a High DosePart 2a: DS-8201a Low DosePart 2b (Exploratory): DS-8201a Low Dose
Any TEAE5048211294
Drug-related TEAEs5047211284
Drug-related TEAEs of CTCAE ≥Grade 3263216483
Any serious TEAE1168250
Drug-related serious TEAEs645100
TEAEs associated with drug discontinuation66881
Related TEAEs associated with drug discontinuation66871
TEAEs associated with dose reduction131911213
Drug-related TEAEs associated with dose reduction111811203
TEAEs associated with dose interruption191612362
Related TEAEs associated with drug interruption171311292
TEAEs associated with death11280
Drug-related TEAEs associated with death00120

Adverse events

Collected over Adverse event (AE) data were collected from Day 0 through Day 47 post last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: DS-8201a Low Dose33/50 (66%)14/50 (28%)50/50 (100%)
Part 1: DS-8201a Medium Dose30/48 (62.5%)11/48 (22.9%)48/48 (100%)
Part 1: DS-8201a High Dose18/21 (85.7%)8/21 (38.1%)21/21 (100%)
Part 2a: DS-8201a Low Dose86/130 (66.2%)42/130 (32.3%)129/130 (99.2%)
Part 2b (Exploratory): DS-8201a Low Dose3/4 (75%)1/4 (25%)4/4 (100%)
Most frequent serious events
Showing 10 of 97
Most frequent serious events
EventPart 1: DS-8201a Low DosePart 1: DS-8201a Medium DosePart 1: DS-8201a High DosePart 2a: DS-8201a Low DosePart 2b (Exploratory): DS-8201a Low Dose
PneumonitisInfections and infestations1/501/481/213/1301/4
COVID-19 pneumoniaInfections and infestations0/500/480/210/1301/4
Post procedural complicationInjury, poisoning and procedural complications0/500/480/210/1301/4
Femur fractureInjury, poisoning and procedural complications0/500/480/210/1301/4
Alanine aminotransferase increasedInvestigations0/500/482/210/1300/4
Aspartate aminotransferase increasedInvestigations0/500/482/210/1300/4
NauseaGastrointestinal disorders0/503/480/213/1300/4
AnaemiaBlood and lymphatic system disorders3/500/480/210/1300/4
CellulitisInfections and infestations3/500/480/211/1300/4
Febrile neutropeniaBlood and lymphatic system disorders0/500/481/210/1300/4
Most frequent other events
Showing 10 of 115
Most frequent other events
EventPart 1: DS-8201a Low DosePart 1: DS-8201a Medium DosePart 1: DS-8201a High DosePart 2a: DS-8201a Low DosePart 2b (Exploratory): DS-8201a Low Dose
NauseaGastrointestinal disorders38/5040/4813/21102/1303/4
Neutrophil count decreasedInvestigations16/5019/4813/2125/1300/4
White blood cell count decreasedInvestigations14/5017/4813/2122/1300/4
AlopeciaSkin and subcutaneous tissue disorders25/5029/488/2162/1302/4
FatigueGeneral disorders22/5025/4811/2170/1302/4
VomitingGastrointestinal disorders23/5021/488/2161/1302/4
StomatitisGastrointestinal disorders12/5016/484/2117/1302/4
Odema peripheralGeneral disorders4/508/480/2113/1302/4
HeadacheNervous system disorders8/5013/482/2132/1302/4
ConstipationGastrointestinal disorders16/5019/4810/2150/1301/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part 1: DS-8201a Low DosePart 1: DS-8201a Medium DosePart 1: DS-8201a High DosePart 2a: DS-8201a Low DosePart 2b (Exploratory): DS-8201a Low DoseTotal
<=18 years000000
Between 18 and 65 years3533161014189
>=65 years1515529064
Age, Continuous
Age, Continuous(years)Part 1: DS-8201a Low DosePart 1: DS-8201a Medium DosePart 1: DS-8201a High DosePart 2a: DS-8201a Low DosePart 2b (Exploratory): DS-8201a Low DoseTotal
Mean57.9 ± 11.355.8 ± 13.054.4 ± 10.555.4 ± 11.949.8 ± 9.255.8 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: DS-8201a Low DosePart 1: DS-8201a Medium DosePart 1: DS-8201a High DosePart 2a: DS-8201a Low DosePart 2b (Exploratory): DS-8201a Low DoseTotal
Female5048211304253
Male000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: DS-8201a Low DosePart 1: DS-8201a Medium DosePart 1: DS-8201a High DosePart 2a: DS-8201a Low DosePart 2b (Exploratory): DS-8201a Low DoseTotal
American Indian or Alaska Native010012
Asian222212471104
Native Hawaiian or Other Pacific Islander100001
Black or African American201115
White24238761132
More than one race110204
Unknown or Not Reported010405
Region of Enrollment
Region of Enrollment(participants)Part 1: DS-8201a Low DosePart 1: DS-8201a Medium DosePart 1: DS-8201a High DosePart 2a: DS-8201a Low DosePart 2b (Exploratory): DS-8201a Low DoseTotal
South Korea77025140
Belgium020709
United States15141036277
Japan16151114056
Italy0108110
United Kingdom00012012
France21017020
Spain108011029
08

Study locations

99 sites
  • Alaska Urological Institute dba Alaska Clinical Research Center
    Anchorage, Alaska 99508, United States
  • Arizona Oncology Associates
    Tucson, Arizona 85704, United States
  • The Regents of the University of California
    Los Angeles, California 90095, United States
  • Sharp Clinical Oncology Research
    San Diego, California 92123, United States
  • University of California San Francisco
    San Francisco, California 94115, United States
  • Sansum Clinic
    Santa Barbara, California 93105, United States
  • Innovative Clinical Research Institute, LLC
    Whittier, California 90603, United States
  • Sylvester Comprehensive Cancer Center - Deerfield Beach
    Boca Raton, Florida 33426, United States
  • Specialist Global Research
    Hialeah, Florida 33012, United States
  • Miami Cancer Institute at Baptist Health, Inc.
    Miami, Florida 33176, United States
  • Piedmont Cancer Institute
    Atlanta, Georgia 30318, United States
  • Straub Medical Center
    Honolulu, Hawaii 96813, United States
  • University of Hawaii
    Honolulu, Hawaii 96813, United States
  • Norton Healthcare
    Louisville, Kentucky 40202, United States
  • University of Louisville Research Foundation
    Louisville, Kentucky 40202, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70120, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • North Shore Hematology Oncology Associates PC DBA NY Cancer and Blood Specialists
    East Setauket, New York 11733, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Aultman Hospital Cancer Center
    Canton, Ohio 44710, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45267, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • UPMC Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • St Francis Hospital
    Greenville, South Carolina 29601, United States
  • Accurate Clinical Research
    Baytown, Texas 77521, United States
  • Texas Oncology, P.A.
    Dallas, Texas 75246, United States
  • Texas Oncology - Memorial City
    Houston, Texas 77024, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • The Methodist Hospital Research Institute
    Houston, Texas 77030, United States
  • Texas Oncology, P.A. - Longview
    Tyler, Texas 75702, United States
  • The University of Texas Health Science Center at Tyler
    Tyler, Texas 75708, United States
  • Virginia Cancer Specialists, PC
    Fairfax, Virginia 22031, United States
  • Providence Regional Medical Center - Everett
    Everett, Washington 98201, United States
  • Imeldaziekenhuis
    Bonheiden, 2820, Belgium
  • Grand Hôpital de Charleroi
    Charleroi, 6000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • CHU Sart Tilman
    Liège, 4000, Belgium
  • AZ Sint-Maarten
    Mechelen, 2800, Belgium
  • University of Calgary
    Calgary, Alberta T2N 4N2, Canada
  • Institut Sainte Catherine
    Avignon, 84918, France
  • CHU Besançon - Hôpital Jean Minjoz
    Besançon, 25030, France
  • Centre Georges François Leclerc
    Dijon, 21079, France
  • CHU Bordeaux - Hôpital Saint André
    Gironde, 33075, France
  • CH de la Rochelle - Hopital St Louis
    La Rochelle, 17019, France
  • Clinique Victor Hugo - Centre Jean Bernard
    Le Mans, 72015, France
  • Hôpital Nord - CHU Marseille
    Marseille, 13915, France
  • Institut Régional du Cancer de Montpellier
    Montpellier, 34298, France
  • Centre Catherine de Sienne
    Nantes, 44202, France
  • Hôpital Saint-Louis - Paris
    Paris, 75475, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, 69495, France
  • CRLCC Eugene Marquis
    Rennes, 35042, France
  • Hôpital d'Instruction des Armees Begin
    Saint-Mandé, 94160, France
  • Centre Paul Strauss
    Strasbourg, 67000, France
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • Ospedale San Raffaele
    Milan, 20132, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milan, 20133, Italy
  • IEO Istituto Europeo di Oncologia
    Milan, 20141, Italy
  • Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)
    Monza, 20900, Italy
  • Ospedale degli Infermi
    Rimini, 47923, Italy
  • Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona
    Torrette, 60020, Italy
  • NHO Shikoku Cancer Center
    Matsuyama, Ehime 791-0280, Japan
  • Toranomon Hospital
    Minatoku, Tokyo-To 105-8470, Japan
  • Aichi Cancer Center Hospital
    Aichi, 464-8681, Japan
  • National Cancer Center Hospital East
    Chiba, 277-8577, Japan
  • NHO Kyushu Cancer Center
    Fukuoka, 811-1395, Japan
  • Hakuaikai Sagara Hospital
    Kagoshima, 892-0833, Japan
  • Kanagawa Cancer Center
    Kanagawa, 241-0815, Japan
  • Kindai University Hospital
    Osaka, 589-8511, Japan
  • National Cancer Center Hospital
    Tokyo, 104-0045, Japan
  • St. Luke's International Hospital
    Tokyo, 104-8560, Japan
  • Cancer Institute Hospital of JFCR
    Tokyo, 135-8550, Japan
  • Kyungpook National University Chilgok Hospital
    Daegu, 41404, South Korea
  • National Cancer Center
    Goyang-si, 10408, South Korea
  • Seoul National University Bundang Hospital
    Seongnam-si, 13620, South Korea
  • Korea University Anam Hospital
    Seoul, 02841, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Severance Hospital, Yonsei University
    Seoul, 03722, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • Hospital Infanta Cristina
    Badajoz, 6080, Spain
  • Hospital Universitari Quiron Dexeus
    Barcelona, 08028, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • ICO l´Hospitalet - Hospital Duran i Reynals
    Barcelona, 08908, Spain
  • Hospital Quiron Barcelona
    Barcelona, 8023, Spain
  • MD Anderson Cancer Centre
    Madrid, 28033, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Clinico Universitario Virgen de la Victoria
    Málaga, 29010, Spain
  • Hospital Universitario Virgen Macarena
    Seville, 41009, Spain
  • Instituto Valenciano de Oncologia IVO
    Valencia, 46009, Spain
  • Derriford Hospital
    Plymouth, Devon PL6 8BQ, United Kingdom
  • Queen Mary University of London
    London, Greater London EC1M 6BQ, United Kingdom
  • University College London Hospitals
    London, Greater London NW1 2PG, United Kingdom
  • Western General Hospital
    Edinburgh, Lothian Region EH4 2XU, United Kingdom
  • Nottingham University Hospitals City Campus
    Nottingham, Nottinghamshire NG5 1PB, United Kingdom
  • Royal Surrey County Hospital
    Guildford, Surrey GU2 7XX, United Kingdom
09

References and documents

Publications

  • Dunton K, Vondeling G, Hancock E, Petrou M, Burn O, Paine A. Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies. Target Oncol. 2022 Nov;17(6):655-663. doi: 10.1007/s11523-022-00923-9. Epub 2022 Nov 7. PubMed 36342619 ↗
  • Rugo HS, Bianchini G, Cortes J, Henning JW, Untch M. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open. 2022 Aug;7(4):100553. doi: 10.1016/j.esmoop.2022.100553. Epub 2022 Aug 11. PubMed 35964548 ↗
  • Bardia A, Harnden K, Mauro L, Pennisi A, Armitage M, Soliman H. Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan. Oncologist. 2022 Aug 5;27(8):637-645. doi: 10.1093/oncolo/oyac107. PubMed 35642907 ↗
  • Modi S. Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study. Future Oncol. 2021 Sep 1;17(26):3415-3423. doi: 10.2217/fon-2021-0427. Epub 2021 Jul 15. PubMed 34263665 ↗
  • Yin O, Iwata H, Lin CC, Tamura K, Watanabe J, Wada R, Kastrissios H, AbuTarif M, Garimella T, Lee C, Zhang L, Shahidi J, LaCreta F. Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan. Clin Pharmacol Ther. 2021 Oct;110(4):986-996. doi: 10.1002/cpt.2291. Epub 2021 Jun 10. PubMed 33999422 ↗
  • Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11. PubMed 31825192 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Mar 2019, 18 months.

Results were first posted in Feb 2020, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2017
First posted
Aug 14, 2017
StartActual
Aug 25, 2017
Primary completionActual
Mar 21, 2019
CompletionActual
May 6, 2024
Results first posted
Feb 17, 2020
Last update
Jun 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03248492
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Aug 14, 2017
Start date
Aug 25, 2017
Primary completion
Mar 21, 2019
Completion
May 6, 2024
Results posted
Feb 17, 2020
Last update
Jun 26, 2025

Study contacts

Global Clinical Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion